МИГРЕНЬ: ОСНОВНЫЕ ПРИНЦИПЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ
https://doi.org/10.17650/1818-8338-2011-4-10-16
Аннотация
В обзоре проанализированы современные рекомендации по лечению мигренозной атаки и профилактике мигрени. Установлено, что для лечения мигренозной атаки доказанной эффективностью обладают ацетилсалициловая кислота, диклофенак натрия, ибупрофен, напроксен, парацетамол, метамизол и их комбинации с кофеином. Для уменьшения тошноты и рвоты рекомендуются метоклопрамид и домперидон. Высокой эффективностью лечения мигренозной атаки обладают триптаны. Для профилактики мигрени применяют метопролол, пропранолол, флунаризин, препараты вальпроевой кислоты. Препаратами 2-й линии для профилактики мигрени являются амитриптилин, венлафаксин, напроксен, бисопролол.
Об авторах
О. Р. Есин
ГОУ ДПО Казанская государственная медицинская академия
Россия
Россия
М. В. Наприенко
ГОУ ВПО 1-й МГМУ им. И.М. Сеченова
Россия
Россия
Р. Г. Есин
ГОУ ДПО Казанская государственная медицинская академия
Россия
Россия
Список литературы
1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia 2004; 24 (Suppl 1):9–160.
2. Табеева Г.Р., Азимова Ю.Э. Профи лактическое лечение мигрени. Практическое руководство для врачей. М.: IF-пресс, 2009.
3. DeVries J.M., Spierings E.L.H. Migraine. In: N.R. Mehta, G.E. Maloney, D.S. Bana, S.J. Scrivani, eds. Head, face, and neck pain: science, evaluation, and management. An interdisciplinary approach. Weinheim: John Wiley & Sons, 2009; p. 108–30.
4. Lipton R.B., Stewart W.F., Diamond S., et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41(7):646–57.
5. Leonardi M., Steiner T.J., Scher A.T., Lipton R.B. The global burden of migraine: measuring disability in headache disorders with WHO; Classification of Functioning Disability and health (ICF). J Headache Pain 2005; 6:429–40.
6. Осипова В.В. Качество жизни при мигрени: роль коморбидных нарушений. http://headache-society.ru/publikatsii/kachestvo-zhizni-pri-migreni-rolkomorbidnyih-narusheniy.html
7. Silberstein S., Tepper S., Brandes J., et al. Randomised placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004;62:1552–7.
8. Tfelt-Hansen P., Block G., Dahlof C., et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765–86.
9. Diener H.C., Bussone G., de Liano H., et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24:947–54.
10. Kloster R., Nestvold K., Vilming S.T. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12:169–71.
11. Gobel H., Heinze A., Niederberger U., et al. Efficacy of phenazone in the treatment of acute
12. migraine attacks: a double-blind, placebocontrolled, randomized study. Cephalalgia 2004; 24:888–93.
13. Tulunay F.C., Ergun H., Gulmez S.E., et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, crossover, randomized, placebo-controlled, multi-center study. Funct Neurol 2004;19:197–202.
14. Lipton R.B., Baggish J.S., Stewart W.F., et al. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, populationbased
15. study. Arch Intern Med 2000; 160:3486–92.
16. Diener H., Pfaffenrath V., Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005;25:776–87.
17. Goldstein J., Silberstein S.D., Saper J.R., et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, doubleblind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006; 46:444–53.
18. Limmroth V., May A., Diener H.C. Lysine-acetylsalicylic acid in acute migraine attacks. Eur Neurol 1999;41:88–93.
19. Bigal M.E., Bordini C.A., Tepper S.J., Speciali J.G. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002;42:862–71.
20. Tfelt-Hansen P., Henry P., Mulder L.J., et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;
21. :923–6.
22. Diener H.C, Bussone G., de Liano H., et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia
23. ;24:947–54.
24. Lampl C., Voelker M., Diener H.C. Efficacy and safety of 1000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007; 254:705–12.
25. Обращение лекарственных средств. Реестр зарегистрированных лекарственных средств и типовых клинико-фармакологических статей. http://www.regmed.ru/
26. Энциклопедия лекарств и товаров аптечного ассортимента. http://www.rlsnet.ru/
27. Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984;4:85–90.
28. Schulman E., Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs.
29. Headache 2003;43:729–33.
30. Friedman B.W., Corbo J., Lipton R.B., et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005;64:463–8.
31. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol 1991;31:314–22.
32. Christie S., Gobel H., Mateos V., et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003;49:20–9.
33. Diener H.C., Reches A., Pascual J. et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised,
34. double-blind, placebo controlled comparison. Eur Neurol 2002;47:99–107.
35. Lainez M.J., Galvan J., Heras J., Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14:269–75.
36. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668–75.
37. Goadsby P.B., Lipton R.B., Ferrai M.D. Migraine: current understanding and treatment. N Engl J Med 2002;346:257–70.
38. Diamond M., Hettiarachchi J., Hilliard B., et al. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004;44:209–16.
39. Bigal M.E., Serrano D., Buse D., et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157–68.
40. Limmroth V., Kazarawa S., Fritsche G., Diener H.C. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. Lancet 1999;353:378.
41. Katsarava Z., Fritsche G., Muessig M., et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001;57:1694–8.
42. Данилов А.Б., Глембоцкая Г.Т., Козуб О.В. Фармакоэкономические аспекты мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова 2011;(4):79–81.
43. Brandes J.L., Kudrow D., Stark S.R., et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297:1443–54.
44. O’Quinn S., Davis R.L., Guttermann D.L., et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. Cephalalgia 1999;19:223–31.
45. Welch K.M., Mathew N.T., Stone P., et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687–95.
46. Velentgas P., Cole J.A., Mo J., et al. Severe vascular events in migraine patients. Headache 2004;44:642–51.
47. Hall G., Brown M., Mo J., MacRae K.D. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563–8.
48. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991; 325:316–21.
49. Tepper S.J., Cochran A., Hobbs S., Woessner M. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998;52:31–5.
50. Tfelt-Hansen P., Ryan R.E. Jr. Oral therapy for migraine: comparisons between rizatriptan
51. and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000;
52. (9 Suppl 2):19–24.
53. Leniger T., Pageler L., Stude P., et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005;45:42–6.
54. Soyka D., Taneri Z., Oestreich W., Schmidt R. Flunarizine i.v. in the acute treatment of the migraine attack. A double-blind placebo-controlled study. Cephalalgia 1988;8(Suppl 8):35–40.
55. Holroyd K.A., Penzien D.B., Cordingley G.E. Propranolol in the management of recurrent migraine: a metaanalytic review. Headache 1991;31:333–40.
56. van de Ven L.L., Franke C.L., Koehler P.J. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 1997;17:596–9.
57. Diener H., Matias-Guiu J., Hartung E., et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002;22:209–21.
58. Freitag F., Collins S., Carlson H. et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652–9.
59. Silberstein S.D., Lipton R.B., Dodick D.W., et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47:170–80.
60. Lampl C., Buzath A., Klinger D., Neumann K. Lamotrigine in the prophylactic treatment of migraine aura — a pilot study. Cephalalgia 1999;19:58–63.
61. Ziegler D.K., Hurwitz A., Preskorn S., et al. Propranolol and amitriptyline in prophylaxis of mi- graine: pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825–30.
62. Silberstein S., Mathew N., Saper J., Jenkins S. Botulinum toxin type A as a migraine preventive
63. treatment. Headache 2000;40:445–50.
64. Evers S., Afra J., Frese A., et al. EFNS guideline on the drug treatment of migraine —revised report of an EFNS task force. Eur J Neurol 2009;16:968–81.
65. Sargent J., Solbach P., Damasio H., et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985;25:320–4.
66. Mannix L.K., Savani N., Landy S., et al. Efficacy and tolerability of naratriptan for shortterm prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037–49.
67. Evers S., Kropp P., Pothmann R., et al. Therapie idiopathischer Kopfschmerzen im Kindes- und Jugendalter. Nervenheilkunde 2008;27:1127–37.
68. Evers S. Drug treatment of migraine in children. A comparative review. Paediatr Drugs 1999;1:7–18.
69. Lewis D., Ashwal S., Hershey A., et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004;63:2215–24.
Рецензия
Для цитирования:
Есин О.Р., Наприенко М.В., Есин Р.Г. МИГРЕНЬ: ОСНОВНЫЕ ПРИНЦИПЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ. Клиницист. 2011;5(4):10-16. https://doi.org/10.17650/1818-8338-2011-4-10-16
For citation:
Esin O.R., Naprienko M.V., Esin R.G. MIGRAINE: BASIC PRINCIPLES OF TREATMENT AND PREVENTION. The Clinician. 2011;5(4):10-16. (In Russ.) https://doi.org/10.17650/1818-8338-2011-4-10-16
Просмотров: 1390
Послать статью по эл. почте 